Healthcare Supplies
-
Eli Lilly's Zepbound Shows Promise in Heart Failure Patients
Eli Lilly's Zepbound & Novo Nordisk's Wegovy show health benefits beyond weight loss, influencing investment strategies in pharmaceutical stocks.
-
AbbVie Stock in Focus with Strategic Cerevel Acquisition
AbbVie (ABBV) acquires Cerevel, enhancing its drug portfolio and opening new growth avenues in neuroscience for investors in ABBV stock.
-
BAYRY Stock: Bayer Faces Major Legal and Drug Dev Setbacks
Bayer's legal and pharmaceutical setbacks are something investors should pay attention to. These issues could impact BAYRY stock value and guide...
-
Mapping the Future of Biopharma: Insights from McKinsey's Helix Report
Explore the McKinsey Helix Report and discover insights into the future success of the biopharmaceutical industry.
-
IPO Outlook: BIAF, HPCO, WLDS
The week ahead's IPOs previewed here are bioAffinity Technologies (NASDAQ: BIAF), Hempacco (NASDAQ: HPCO) and Wearable Devices (NASDAQ: WLDS).
-
Daily Stock Watch: Figs (NYSE: FIGS) Stock Slips
After a short-lived rally, the Figs (NYSE: FIGS) stock price dips. Is FIGS stock a good long-term investment?
-
Daily Stock Watch: EAR Stock Rockets by 120%
Hearing aid company Eargo Inc (NASDAQ: EAR) has seen its share price soar in the latest chapter of a topsy turvy year for the business. But is EAR...
-
Bausch + Lomb IPO: A Good Investment?
Bausch + Lomb is about to go public with an IPO, so we're taking a look at the stock to see if there's a clear case for investing.
-
SRRA Shares Higher: Sierra Oncology Cancer Drug Shines in Testing
Sierra Oncology (NASDAQ: SRRA) shares leapt by more than 25% on Wednesday after a breakthrough in the firm's quest to commercialize a blood cancer...
-
Investing in Shroom Stocks
Shroom stocks are increasingly popular and the upside potential is huge. Here's an overview of the sector and a list of stocks available.
-
Is Pfizer a Good Investment?
Pfizer offers a lot more to shareholders than a boost from COVID-19 vaccine revenues. With growth potential ahead, it may be undervalued.